BioCentury | Jul 21, 2020
Deals

With deal for Tizona, Gilead places latest bet on cancer immunosuppression

...readout. The deal gives Gilead Sciences Inc. (NASDAQ:GILD) a chance to gain full ownership of TTX-080...
...Tizona’s conversations with Gilead began as discussions around licensing of TTX-080 and a second asset, TTX-040...
...integrate many companies simultaneously. Gilead’s option for Tizona also gives it the opportunity to obtain TTX-040...
BioCentury | Feb 2, 2018
Product R&D

It’s the assay...

...the potency of tetracycline more than 100-fold compared with the standard assay, whereas the neurotoxin TTX...
BioCentury | Apr 22, 2013
Emerging Company Profile

SiteOne's saxy synthesis

...membrane permeability. SiteOne said it is aware of only one other compound targeting site 1 -tetrodotoxin...
...III trials for cancer-related pain. In 2010, a DMC said a Phase III trial of tetrodotoxin...
...believes its synthetic platform could improve the low therapeutic index of natural toxins such as tetrodotoxin...
BioCentury | Jan 24, 2011
Company News

CK Life Sciences, Wex deal

...on July 9, the last trading day before the original deal was announced. Wex's TTX tetrodotoxin...
BioCentury | Oct 4, 2010
Clinical News

Tetrodotoxin: Phase III ongoing

...DMC informed the company that the ongoing double-blind, placebo-controlled, Canadian Phase III TEC-006 trial of tetrodotoxin...
...trial until a decision is made. Wex Pharmaceuticals Inc. (TSX:WXI), Vancouver, B.C. Product: Tetrodotoxin ( TTX...
BioCentury | Jul 19, 2010
Company News

CK Life Sciences, Wex deal

...review the offer. Wex's TTX tetrodotoxin is in Phase III testing to treat cancer-related pain. TTX...
BioCentury | Jan 28, 2010
Financial News

Wex raises $32.6 million

...offering. Shareholders were eligible to purchase one-and-a-half shares for each existing share held. Wex's Tectin tetrodotoxin...
BioCentury | Dec 1, 2009
Financial News

Wex planning offering

...Shareholders will be eligible to purchase one-and-a-half shares for each existing share held. Wex's Tectin tetrodotoxin...
BioCentury | Aug 22, 2005
Clinical News

Tetrodin tetrodotoxin: Phase IIa data

...In a double-blind, placebo-controlled Phase IIa trial in 14 methadone-maintained subjects, a 4-day pre-treatment with tetrodotoxin...
...was well tolerated but did not alleviate withdrawal symptoms. Subjects received subcutaneous 30 µg twice-daily tetrodotoxin...
...or until it can find a partner. Wex Pharmaceuticals Inc. (TSE:WXI), Vancouver, B.C. Product: Tetrodin tetrodotoxin...
BioCentury | Jan 19, 2004
Strategy

Ion channel players

...located in hippocampus Modulator of undisclosed mechanism Age-related memory loss Preclin (w/ Yamanouchi) International Wex Tetrodin...
Items per page:
1 - 10 of 14